Aarti Pharmalabs Ltd.

₹650.85

-27.8 (-4.1%)

AARTIPHARM Share Price

Pharmaceuticals & Biotechnology

As on March 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 5,927 Cr

P/E Ratio21.66

Dividend Yield0.15 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	675.66	Bearish
10-DMA	688.46	Bearish
20-DMA	698.4	Bearish
50-DMA	736.4	Bearish
100-DMA	747.47	Bearish
200-DMA	814.24	Bearish

Historical Performance

1 Year

-11.9%

3 Years

116.7%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	21,151	18,526	19,452	11,999	---
Total Expenditure	16,507	14,666	16,032	9,947	---
Other Income	101	49	23	42	---
Operating Profit	4,745	3,909	3,444	2,095	---
Interest	269	172	211	120	---
Depreciation	869	732	625	421	---
Profit Before Tax	3,607	3,005	2,608	1,554	---
Consolidated Net Profit	2,724	2,169	1,935	1,223	---
Adjusted EPS	30	24	21	4,890	---

Compounded Sales Growth

10 Years:N/A

5 Years:N/A

3 Years:12

TTM:2.7

Compounded Profit Growth

10 Years:628.5

5 Years:628.5

3 Years:17.4

TTM:4.7

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:29.1

TTM:-11.9

Return on Equity

10 Years:N/A

5 Years:-0.2

3 Years:21.4

last year:30.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	453	453	453	2	2
Total Reserves	19,429	17,115	15,132	13,409	---
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	2,594	1,307	849	728	---
Other Current Liabilities	735	458	383	119	---
Short Term Borrowings	2,928	2,639	2,138	3,377	---
Total Liabilities	29,064	25,821	22,440	20,399	2
Capital Work in Progress	3,066	785	622	1,652	---
Long Term Loans & Advances	441	294	178	101	---
Currents Investments	476	704	510	---	---
Short Term Loans and Advances	873	720	400	820	---
Total Current Assets	13,222	13,456	11,630	10,282	2
Total Assets	29,064	25,821	22,440	20,399	2
Adjusted Book Value	219	194	172	53,647	9

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 21.66, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 29.1%, indicating sustained price appreciation.
The stock carries a beta of 1.1, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹4745 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹21151 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 840565.7

No. of Shares: 1291 (Approx)

Performance:-15.9%

P/L: ₹-159434.3

NIFTY Performance: 3.4%

1 day Top Gainers